Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Patients with extensive-stage SCLC often respond to induction therapy, but the disease tends to progress rapidly after cytotoxic therapy ends, said Jared Weiss, MD, of the University of North Carolina ...

The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of care radiation therapy could improve the proportion of patients achieving ...

Focus on potential partnership and strategic opportunities for the Company’s stem cell therapy program for Alzheimer’s disease Recent Type B meeting with FDA provided alignment on a planned single, ...

IFx-Hu2.0 is designed to overcome primary resistance to checkpoint ... compared to Keytruda® plus placebo in first line treatment for advanced or metastatic Merkel Cell Carcinoma.

IFx-Hu2.0 is designed to overcome primary resistance to checkpoint inhibitors ... trials in melanoma and advanced or metastatic Merkel cell carcinoma (MCC). "Like our planned Phase 3 accelerated ...

Secondary infertility is a unique, often silent struggle, faced by parents who are unable to conceive or carry another pregnancy to term after having one or more children. Unlike primary ...

Cancers are usually grouped by where they first started (the primary ... cells line certain organs of the body, and release substances such as mucus or digestive juices. At least 65 out of 100 CUP (65 ...

Cancer of unknown primary (CUP) means that cancer spread (secondary cancer ... Most cancers are cancers of the epithelial cells. Epithelial cells are found in the skin or tissues that line or cover ...

As for the 7.5-mg dose of upadacitinib, neither the primary nor secondary endpoints were significantly ... I would not use this drug as a first-line treatment. We do not do that for rheumatoid ...